{"id":"W2947468545","doi":"10.1186/s12885-019-5266-4","title":"Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma","year":2019,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"AstraZeneca Canada; AstraZeneca","keywords":"Medicine; Durvalumab; Tremelimumab; Immunotherapy; Oncology; Clinical endpoint; Head and neck squamous-cell carcinoma; Internal medicine; Response Evaluation Criteria in Solid Tumors; Surgical oncology; Common Terminology Criteria for Adverse Events; Adverse effect; Phases of clinical research; Radiation therapy; Radiology; Head and neck cancer; Toxicity; Cancer; Clinical trial; Nivolumab; Ipilimumab","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001534833,0.0001703303,0.0007503147,0.00007595775,0.00007085466,0.000009871558,0.00003649748,0.00004037566,0.0001107899],"category_scores_gemma":[0.0000411874,0.0001349554,0.00009027548,0.00008493636,0.0000735982,0.00007074741,0.00002338918,0.00007115801,7.812488e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001280872,"about_ca_system_score_gemma":0.0003506588,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004172474,"about_ca_topic_score_gemma":0.0002856219,"domain_scores_codex":[0.9989669,0.0000336495,0.0002980061,0.0002929607,0.0001753156,0.0002331537],"domain_scores_gemma":[0.9993512,0.0001457308,0.0001142057,0.0002106757,0.0000750653,0.0001031424],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6956514,0.00399326,0.06489862,0.008877022,0.002710705,0.00002783563,0.01421671,0.00001106651,0.05169043,0.0004586332,0.007955462,0.1495088],"study_design_scores_gemma":[0.8893675,0.03955761,0.03140551,0.0005485869,0.0009026038,0.0000435749,0.0004629644,0.003559884,0.002885198,0.00005140774,0.03080074,0.0004144881],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9824394,0.01444781,0.00006432065,0.0004331367,0.0003993459,0.001894226,0.00006901094,0.00001647846,0.0002362591],"genre_scores_gemma":[0.9956679,0.001243898,0.0007937287,0.000258137,0.000256185,0.0002313793,0.000005748615,0.00003045438,0.001512616],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.193716,"threshold_uncertainty_score":0.5503321,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0591299704651508,"score_gpt":0.3773384111575256,"score_spread":0.3182084406923749,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}